Analysts Set Neurogene Inc. (NASDAQ:NGNE) Target Price at $42.50

Neurogene Inc. (NASDAQ:NGNE) has received a consensus rating of “Moderate Buy” from the six brokerages that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $42.50.

A number of equities analysts have recently issued reports on NGNE shares. HC Wainwright restated a “buy” rating and issued a $70.00 price target on shares of Neurogene in a research note on Tuesday, January 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Neurogene in a report on Wednesday, October 8th. Finally, Wall Street Zen downgraded Neurogene from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets grew its holdings in Neurogene by 89.8% during the third quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock valued at $36,000 after purchasing an additional 978 shares during the period. PNC Financial Services Group Inc. lifted its position in shares of Neurogene by 43.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 4,055 shares of the company’s stock valued at $61,000 after buying an additional 1,232 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Neurogene by 17.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock valued at $82,000 after buying an additional 1,059 shares in the last quarter. Bridgeway Capital Management LLC bought a new position in shares of Neurogene during the 3rd quarter valued at approximately $187,000. Finally, Brevan Howard Capital Management LP purchased a new stake in Neurogene in the 3rd quarter worth approximately $223,000. 52.37% of the stock is currently owned by institutional investors.

Neurogene Stock Up 4.5%

Shares of NGNE stock opened at $18.31 on Monday. The company has a 50 day moving average price of $20.02 and a 200-day moving average price of $22.06. Neurogene has a 52 week low of $6.88 and a 52 week high of $37.27. The firm has a market capitalization of $283.62 million, a PE ratio of -4.45 and a beta of 1.60.

Neurogene (NASDAQ:NGNE) last issued its earnings results on Thursday, November 13th. The company reported ($0.99) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $0.27. Analysts anticipate that Neurogene will post -4.27 earnings per share for the current year.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.